VERTEX PHARMACEUTICALS INC / MA Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2010 to Q3 2024.
  • Vertex Pharmaceuticals Inc / Ma Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $185M, a 41% increase year-over-year.
  • Vertex Pharmaceuticals Inc / Ma Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $739M, a 52.7% increase year-over-year.
  • Vertex Pharmaceuticals Inc / Ma annual Share-based Payment Arrangement, Expense for 2023 was $581M, a 18.3% increase from 2022.
  • Vertex Pharmaceuticals Inc / Ma annual Share-based Payment Arrangement, Expense for 2022 was $491M, a 11.3% increase from 2021.
  • Vertex Pharmaceuticals Inc / Ma annual Share-based Payment Arrangement, Expense for 2021 was $441M, a 2.77% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $739M $185M +$53.7M +41% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $686M $154M +$34.9M +29.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $651M $192M +$69.5M +56.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $581M $209M +$97.1M +87.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $484M $131M -$4.7M -3.47% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $489M $119M +$5.4M +4.74% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 $483M $122M -$7.9M -6.06% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $491M $112M -$7.1M -5.99% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $498M $136M +$32.6M +31.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $466M $114M +$9.3M +8.89% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $457M $130M +$15.1M +13.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $441M $119M +$21.5M +22.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $420M $103M +$3.46M +3.48% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $416M $105M -$12.6M -10.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $429M $115M -$506K -0.44% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $430M $97.1M +$5.46M +5.97% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 $424M $99.5M +$14.1M +16.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $410M $117M +$27.5M +30.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $382M $116M +$21.9M +23.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $361M $91.6M +$12.7M +16% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 $348M $85.4M -$112K -0.13% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-30
Q2 2019 $348M $89.7M +$7.25M +8.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-31
Q1 2019 $341M $93.8M +$15.7M +20% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q4 2018 $325M $78.9M +$2.7M +3.54% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-11
Q3 2018 $322M $85.5M +$11.1M +14.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $311M $82.4M +$9.34M +12.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $302M $78.1M +$8.7M +12.5% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-01
Q4 2017 $293M $76.2M +$14.2M +23% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-13
Q3 2017 $279M $74.5M +$13.2M +21.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-25
Q2 2017 $266M $73.1M +$11.2M +18% Apr 1, 2017 Jun 30, 2017 10-Q 2018-07-26
Q1 2017 $255M $69.4M +$14M +25.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
Q4 2016 $241M $62M +$17.4M +38.9% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-13
Q3 2016 $223M $61.2M -$4.53M -6.88% Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-30
Q2 2016 $228M $61.9M -$1.32M -2.09% Apr 1, 2016 Jun 30, 2016 10-Q 2017-07-28
Q1 2016 $229M $55.5M -$1.91M -3.33% Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-28
Q4 2015 $231M $44.6M +$2.26M +5.34% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-15
Q3 2015 $229M $65.7M +$19.6M +42.5% Jul 1, 2015 Sep 30, 2015 10-Q 2016-10-31
Q2 2015 $209M $63.3M +$20.8M +49% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-01
Q1 2015 $188M $57.4M +$10.8M +23.2% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-03
Q4 2014 $178M $42.4M Oct 1, 2014 Dec 31, 2014 10-K 2017-02-23
Q3 2014 $46.1M Jul 1, 2014 Sep 30, 2014 10-Q 2015-10-30
Q2 2014 $42.4M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-04
Q1 2014 $46.6M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-04
Q4 2012 $114M $27.2M -$1.9M -6.54% Oct 1, 2012 Dec 31, 2012 10-K 2015-02-13
Q3 2012 $116M $27.6M -$1.83M -6.23% Jul 1, 2012 Sep 30, 2012 10-Q 2012-11-06
Q2 2012 $118M $31.4M -$500K -1.57% Apr 1, 2012 Jun 30, 2012 10-Q 2012-08-08
Q1 2012 $118M $27.7M -$191K -0.69% Jan 1, 2012 Mar 31, 2012 10-Q 2012-05-10
Q4 2011 $118M $29.1M +$5.48M +23.2% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-11
Q3 2011 $113M $29.4M +$5.65M +23.8% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-06
Q2 2011 $107M $31.9M +$7.43M +30.4% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-08
Q1 2011 $99.7M $27.9M +$8.55M +44.2% Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-10
Q4 2010 $91.1M $23.6M Oct 1, 2010 Dec 31, 2010 10-K 2013-03-01
Q3 2010 $23.8M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-03
Q2 2010 $24.4M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
Q1 2010 $19.3M Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.